Partnerships

Under terms of the deal, Gubra will receive an initial $350 million payment and could earn up to $1.875 billion more in development and sales milestones for the potential weight loss drug.

Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights to commercialize the treatment outside of North America.

Under terms of the deal, Epitopea and Merck will work to identify Cryptigen tumor-specific antigens through Epitopea’s CryptoMap platform.

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five expanding therapeutic areas.

New partnerships aim to expand Teva’s biosimilar portfolio and enhance access to high-cost biologics across key markets.